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Abstract
Objectives—Bacterial vaginosis (BV) is a condition characterized by a disturbed vaginal 
ecosystem which fluctuates in response to extrinsic and intrinsic factors. BV recurrence is 
common. To explore whether consistent condom use was associated with BV occurrence or 
recurrence, we compared the effect of condom use on BV prevalence after six months, among 
women with and without BV at baseline.
Methods—We used data from a randomized controlled trial, conducted among female sex 
workers in Madagascar during 2000–2001, that assessed the impact of adding clinic-based 
counseling to peer education on sexual risk behavior and sexually transmitted infection incidence. 
BV was diagnosed at two time points (baseline and six months) according to modified Amsel 
criteria. Consistent condom users were women reporting no unprotected sex acts with clients in 
the past month or non-paying partners in the past year. Adjusted prevalence ratios (PRs) and 95% 
confidence intervals (CIs) were calculated using multivariable regression models.
Results—At baseline, 563 (56%) women had BV. Of those, 360 (72%) had BV at 6 months, 
compared to 158 (39%) of those without BV at baseline. The adjusted 6-month PR for BV 
comparing consistent to inconsistent condom users was 0.99 (95% CI: 0.85–1.13) among women 
with BV at baseline and 0.62 (95% CI: 0.30–0.94) among women without BV at baseline.
Conclusions—Consistent condom use was associated with reduced BV prevalence at 6 months 
for women who were BV-negative at baseline, but had no effect among women who were BV-
positive at baseline. Male condoms appeared to protect against BV occurence, but not BV 
recurrence.
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INTRODUCTION
Bacterial vaginosis (BV) is the most common cause of abnormal vaginal discharge in 
women of reproductive age (Hapsari et al, 2006). It is characterized by a reduction in vaginal 
lactobacilli with an associated increase in BV-associated organisms such as Gram-negative 
and anaerobic bacteria (Gardenerella vaginalis, Bactroides sp, Provetella sp, Mobiluncus sp, 
and Peptostreptococcus sp) and genital mycoplasmas (U. urealyticum and M. hominis) 
(Hillier et al, 1993). BV has been associated with adverse pregnancy outcomes including 
premature rupture of membranes, premature delivery, low birth weight, and post-partum and 
post-abortion endometritis (Hillier et al, 1995; Kurki et al, 1992). Women with BV are also 
at increased risk of sexually transmitted infections (STIs) (Wiesenfeld et al, 2003)), 
including HIV (Taha et al, 1998). However, the cause of the microbial alteration leading to 
BV is not fully understood.
BV-associated organisms are also found in non-chlamydial non-gonococcal urethritis in men 
(Workowski & Berman, 2006). In addition, risk factors associated with BV include 
behaviors that increase STI risk, such as having new or multiple sexual partners (Bradshaw 
et al, 2005), suggesting that BV might be sexually transmitted. However, other factors not 
known to be associated with sexual activity (vaginal douching, lack of vaginal lactobacilli) 
have also been linked with BV (Ness et al, 2002). Moreover, as many as 25% of girls 14–19 
years old in the US have BV, irrespective of sexual experience (Gottlieb et al, 2008) and BV 
may also present as a natural variability associated with menstrual cycle (Morison et al, 
2005). Thus BV may be acquired through both sexual behaviors and non-sexual factors.
BV can occur as a new acquisition (BV occurrence) or re-emergence of a previous episode 
(BV recurrence). The two antibiotics used in the recommended first-line therapy 
(metronidazole and clindamycin (Anonymous, 1998) have imperfect cure rates ranging from 
80% – 90% at 1 month (Koumans et al, 2002) and recurrence rates as high as 69% in the 
first year after treatment have been described (Bradshaw et al., 2006). In epidemiologic 
studies it can be difficult to distinguish between BV occurrence and recurrence. This 
difficulty is exacerbated because a “cured” BV case is simply the normalization of vaginal 
flora and symptoms rather than the eradication of any particular pathogen (Anonymous, 
1998). This lack of differentiation may be the reason behind inconclusive results from 
studies of BV risk factors, particularly factors associated to the sexual route of BV 
acquisition. For example, several studies have demonstrated that condoms are protective 
against BV (Hutchinson et al, 2007; Smart et al, 2004), whereas others found evidence of 
effect that condoms prevent BV (Bradshaw et al, 2005; Schwebke et al, 2004). In addition, 
treatment of the male sex partners of women with BV has not been beneficial in preventing 
the recurrence of BV in women (Vutyavanich et al, 1993), calling into question whether 
sexual transmission is a likely route of infection. However, beside the Hutchinson study, all 
those studies did not clearly differentiate between repeat and first incidence of BV. 
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Assuming that sexual factors are associated only with the initial BV acquisition but not with 
re-emergence of a persistent episode, analyzing the association between condom use and a 
single, heterogeneous outcome capturing all types of BV cases could lead to an 
underestimation of the importance of condom and therefore of the sexual route in BV 
acquisition.
In this secondary data analysis, we examined the effect of consistent condom use on BV risk 
at six months. We hypothesized that repeat BV is more likely due to a re-emergence of a 
persistent, existing BV infection rather than acquisition of a new case of BV, and therefore 
that consistent condom use was more likely to have a stronger protective effect on women 
who were BV-negative at baseline than on women who were BV-positive at baseline.
METHODS
Data and procedures
We used data from a randomized controlled trial (RCT), conducted among female sex 
workers (FSWs) in Madagascar in 2000–2001, that was designed to assess the impact of 
adding clinic-based counseling to peer education on sexual risk behavior and STI incidence 
(Feldblum et al., 2005; Hoke et al., 2007). Self-identified active FSWs (n=1,000), age 16 or 
older, with no signs of pregnancy, were individually randomized to receive condom 
counseling by peer educators (peer-only arm), or peer counseling plus clinic-based 
counseling (peer+clinic). Participants were followed for 18 months in two public 
dispensaries in the capital city, Antananarivo, and in the principal port city, Tamatave. The 
details of the randomization process and the main findings from the intervention have been 
published elsewhere (Feldblum et al., 2005; Hoke et al., 2007).
The study had two phases: an initial phase (from baseline through 6 months) during which 
only male condoms were available, and a second phase when both male and female condoms 
were promoted. The analyses presented here used data from the first 6 months of the study 
only. After enrollment, each study participant returned to the clinic every 2 months for 
follow-up visits. At each visit, data on sexual activity and condom use were collected 
through face-to-face interviews. In addition, at the baseline and 6-month visits, one clinician 
at each study site examined participants and collected specimens for laboratory testing 
(Feldblum et al., 2005). After examination, all participants were treated presumptively for 
gonococcal and chlamydial infection with ciprofloxacin (500 mg orally in a single dose) and 
azithromycin (1 g orally in a single dose). Treatment was given one week later for syphilis 
(benzathine penicillin, three doses of 2.4 million units IM at 1-week intervals for latent 
syphilis of unknown duration, one dose for early syphilis), candidiasis (nystatin, one ovule 
(100 000 IU) per night for 10 consecutive nights), and trichomoniasis and BV 
(metronidazole, 2 g orally in a single dose) as needed.
Variable definition
Outcome—This analysis uses BV data from two time points: baseline and 6 months. BV 
was classified according to modified Amsel criteria (Workowski & Berman, 2006). Women 
were BV-positive if at least three of the following criteria were met: pH of the vaginal fluid 
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>4.5, homogenous vaginal discharge, clue cells on microscopic examination, or a positive 
amine test (the “whiff” test).
Exposure—In the RCT, condom use was measured differently for clients (paying sex 
partners) and non-paying partners. For clients, participants were asked at each visit (once 
every two months) the number of sex acts they had had with clients over the preceding 30 
days and how many of those acts were protected by condoms. For non-paying partners, this 
information was asked for the preceding 12 months. Women who reported no unprotected 
sex with clients at all 3 follow-up visits (2, 4, and 6 months) and no unprotected sex with 
non-paying partners in the past 12 months at the 6-month visit were classified as consistent 
condom users. All other participants were classified as inconsistent users.
We also assessed several potential confounding factors, including age, study site, 
randomization group, marital status (married/cohabiting, single (with or without a steady 
partner), and widowed/separated/divorced), average number of sex partners in the week 
preceding each of the 3 follow-up visits, and vaginal cleansing practices (use of water only 
vs. use of water plus other products).
Statistical analysis
Prevalence ratios (PR) assessing the effect of consistent condom use on BV risk at 6 months 
were calculated among women with and without BV at baseline. Prior to multivariable 
modeling, we first examined the bivariate association between consistent condom use and 
BV at six months. We used the Mantel-Haenszel test of homogeneity to assess if the crude 
effect of consistent condom use on BV differed by baseline BV status.
The odds ratio was not an appropriate choice for the measure of effect because our outcome 
(BV) was very common (57.5%) (Altman et al., 1998). Binomial models did not converge. 
To estimate the adjusted PRs and their confidence intervals, the method recently proposed 
by Localio et al. (Localio et al., 2007) was used. Standard errors, estimated using bootstrap 
methods, were used to calculate the 95% confidence intervals (CI) for the adjusted PRs.
Prior knowledge and bivariate analyses were used to select variables that were included in 
the initial model. We also included an interaction term between BV at baseline and 
consistent condom use in the initial model, to allow computation of the effect of consistent 
condom use on BV at 6 months in each stratum of baseline BV status. We used likelihood 
ratio tests (LRT) to assess the contribution of the interaction term to the fit of the model. The 
significance level for the test of homogeneity and the LRT for the interaction term was 
α=0.10 (Kleinbaum & M., 2002). To arrive at the most parsimonious model that captured 
the effect of consistent condom use on 6-month BV risk, we used a manual, backward 
elimination, change-in-estimate strategy to eliminate covariates that did not substantially 
affect the effect estimate (the change-inestimate criterion was 10%). Regardless of the 
change in the effect estimate, we retained two additional variables in the final multivariable 
model – use of hormonal contraception and vaginal cleansing practices – because of a priori 
hypotheses about their role in BV risk.
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Of the 1,000 women that were randomized at baseline, 901 (90%) returned for the 6-month 
visit. By design, 50% of participants were from Antananarivo and 50% from Tamatave. 
Participants were also equally split between the two randomization groups (Table 1). At 
baseline 65% of women were single, and the mean age was 28 years. Half reported more 
than six paying sexual partners a week. During at least one of the three follow-up visits, 25% 
of women reported using hormonal contraception, 62% reported having had sex with a non-
paying partner within the past week, and all reported vaginal cleansing. Most (68%) women 
reported using water only for vaginal cleansing.
BV was highly prevalent among study participants. At baseline, 563 women (56%) had BV 
and virtually the same percentage of BV-positives was observed at 6 months (57%). Fifty 
four women (6%) were classified as consistent condom users over the six-month follow-up. 
In bivariate analyses, 360 participants (72%) who had BV at baseline were again BV-
positive at 6 months, compared to 158 (39%) of those without BV at baseline who were BV-
positive at 6 months. Participants who were younger, single, used a product other than water 
for vaginal cleansing, used no hormonal contraception, from Tamatave, or with BV at 
baseline were less likely to use condoms consistently and more likely to be diagnosed with 
BV at 6 months. In addition, women who reported a non-paying sexual partner in the past 
week were less likely to be diagnosed with BV at 6 months. The unadjusted PR for BV at 
the 6-month visit comparing consistent to inconsistent condom users was 0.60 (95%CI: 0.41, 
0.86) among all women, 0.98 (95% CI: 0.72, 1.33) among women with BV at baseline, and 
0.46 (95% CI: 0.23, 0.90) among those without BV at baseline. The Mantel-Haenszel test 
for homogeneity of the PRs by baseline BV status was significant (p=0.01) (Table 2).
In the initial multivariable model including BV at baseline, the interaction term between BV 
at baseline and consistent condom use, and all potential confounders, the LRT for the 
interaction term met our criteria for significance (see Methods) (p=0.08). The final 
multivariable model adjusted for use of hormonal contraception, age, average number of 
paying sex partner in the past week, and vaginal cleansing practices. The adjusted PR for the 
effect of consistent condom use on BV at six months was 0.70 (95%CI: 0.38, 1.01) among 
all women, 0.98 (95% CI: 0.85, 1.13) among women with BV at baseline, and 0.62 (95% CI: 
0.30, 0.94) among those without BV at baseline (Table 2).
DISCUSSION
BV was very common among study participants, consistent with previous observations in 
Madagascar that sexual and reproductive tract infections are highly prevalent among women 
seeking primary care for genitourinary infections and highest among female sex workers 
(Behets et al., 2001; Behets et al., 2005). Only 6% of participants were classified as 
consistent condom users during the 6-month follow-up period. This low level of condom use 
matches the high rates of STIs described in other reports from this trial (Feldblum et al., 
2005; Hoke et al., 2007).
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Alternative definitions of consistent condom use were considered: (1) condom use at last sex 
with a client at each of the 3 follow-up visits, (2) condom use in all sex acts with clients in 
the past 30 days at each of the 3 follow-up visits, (3) condom use at last sex with a client and 
last sex with a non-paying partner, at each of the 3 follow-up visits, and (4) consistent 
condom as defined above. Condom use was low in general ranging from 66% with definition 
(1) to 6% with definition (4). With each of these definitions, we detected no effect of 
condom use on BV prevalence at 6 months among women with BV at baseline. However, 
among women without BV at baseline, we saw a protective effect of condom use on BV at 6 
months for all 4 definitions. But the magnitude of the strength of the protective association 
between condom use and 6-month BV prevalence increased as the total number of sex acts 
covered by the definition increased (results not shown).
Consistent condom users were women who reported no unprotected sex with clients at all 
the 3 follow-up visits (2, 4, and 6 months) and with non-paying partners in the past 12 
months at the 6-month visit. While this definition does not cover all sex acts during the 
follow-up period, it reduces possible measurement error by shortening the period over which 
women were asked to remember their sexual behavior. Nevertheless, because participants 
were asked to report both the total number of sex acts they had had over a 30-day period 
and, out of these, the number when condoms were used, it is possible that some misreporting 
occurred (recall bias). It is also possible, given that participants were actively counseled to 
use condoms, that some may have overstated the number of acts in which they used 
condoms (social desirability bias). We expect that bias resulting from recall error or social 
desirability, which we hypothesize would lead to an overestimate of condom use, is likely to 
be nondifferential with respect to the outcome (BV status at 6 months), and therefore our 
observed estimates may be biased toward the null. However, given the large difference in 6-
month BV risk between BV-positive and BV-negative women at baseline, we do not think 
that bias is likely to explain our results.
In both unadjusted and multivariate analyses, the effect of consistent condom use was 
different depending on women’s baseline BV status. Among women negative for BV at 
baseline, women who reported using condoms consistently had a significantly lower risk of 
acquiring BV after 6 months. In contrast, consistent condom use did not appear to have any 
effect among those with BV at baseline. These findings suggest that, among those with BV 
at baseline, BV recurrence is not likely to be a new acqusition from a male partner. Our 
results for women without BV at baseline agree with previous studies that suggest that 
consistent condom use reduces BV risk (Hutchinson et al., 2007), and provide additional 
evidence that at least some BV can be acquired sexually (and hence consistent condom use 
is an effective mean to prevent it). The finding that consistent condom use had no effect on 
the risk of repeat BV is also consistent with a study of BV recurrence among Australian 
women. Those authors reported no association between BV recurrence and women’s 
reported number of male sex partners or condom use (Bradshaw et al., 2006).
We note that although our results fit both with our a priori hypothesis about the role of 
condom use on BV and with the sparse prior literature on this topic, these findings alone 
cannot determine whether recurrent BV is simply a reemergence of an existing condition or 
acquisition of a new one through a non-sexual transmission route. BV may be best described 
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as a disturbed ecosystem with resilience fluctuating in response to various extrinsic and 
intrinsic factors (sexual activity, hygiene, host factors, contraceptive choices, etc.). Therefore 
classifying a woman as BV-negative at baseline in this study (one time point) may represent 
misclassification, and given the 6-month interval between the two BV assessments, it is 
difficult to assess accurately whether BV as detected at the 6-month visit was incident or 
prevalent. However, any misclassification is likely to be nondifferential with respect to the 
exposure (condom use), and any bias would push our estimate toward the null. In addition, 
though our findings in women without BV at baseline suggest that BV might be acquired 
through sexual route, studies of the dynamic of BV associated organisms in both male and 
female sex partners are needed to confirm this observation.
We did not perform a test of cure among women treated for BV at the baseline visit. The 
high frequency of BV at 6 months among women with BV at baseline (72%) compared to 
the substantially lower frequency among women without BV at baseline (39%) may suggest 
that oral metronidazole, administered in single dose (as was the recommended treatment at 
the time this study was implemented (Anonymous, 1998), might not be sufficient to 
eradicate BV-associated pathogens. This interpretation is consistent with findings from a 
recent study designed to determine the efficacy of the current standard treatment with oral 
metronidazole for 1 week in the eradication of the bacterial vaginosis biofilm (a complex 
aggregation of microorganisms marked by the excretion of a protective and adhesive matrix) 
(Swidsinski et al., 2008). That study reported that although all patients initially recovered 
from their symptoms, treatment cessation brought about a consistent resurgence of a dense 
and active bacterial biofilm on the vaginal mucosa, primarily consisting of Gardnerella 
vaginalis and Atopobium vaginae. However, the study did not follow participants long 
enough to see whether symptoms reappeared or not.
In conclusion, our results show that though consistent condom use had a protective effect on 
the 6-month prevalence of BV among BV-negative women at baseline, it had no effect on the 
6-month prevalence of BV among women who were classified as BV-positive at baseline.
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